Champions Oncology, Inc.

UEI
K7EZES58U9N8
CAGE
6TDL5
Primary NAICS
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Website
championsoncology.com
Founded
2007
Employees
51-250
Estimated annual revenue
$10M-$50M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Champions Oncology, Inc.'s 2 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
(champions oncology) (sbir topic 355) (direct to phase II) to address the slow growth rate of prostate pdxs by… Contract · HHSN261201700013C National Cancer Institute $1,999,931
Champions oncology, INC in vivo evaluation of ncatss compound in a low passage tumorgraft model of cholangiocarcinoma Contract · HHSN271201500258P National Institute on Drug Abuse $0

Quick answers

What is Champions Oncology, Inc.'s UEI?

Champions Oncology, Inc.'s Unique Entity ID (UEI) in SAM.gov is K7EZES58U9N8.

What is Champions Oncology, Inc.'s CAGE code?

Champions Oncology, Inc.'s CAGE code is 6TDL5.

What is Champions Oncology, Inc.'s primary NAICS code?

Champions Oncology, Inc.'s primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).

Is Champions Oncology, Inc. registered in SAM.gov?

Champions Oncology, Inc.'s SAM.gov registration expired on March 16, 2022.

What is Champions Oncology, Inc.'s most recent federal award?

Champions Oncology, Inc.'s most recent federal contract award is (champions oncology) (sbir topic 355) (direct to phase II) to address the slow growth rate of prostate pdxs by… (HHSN261201700013C), from National Cancer Institute, on September 19, 2017.

On GovTribe

See Champions Oncology, Inc.'s full federal record

  • Federal contract awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login